News &amp; Updates

Personalizing upfront treatment options for advanced EGFRm NSCLC

26 May 2025 by

This article will summarize the latest developments in the first-line management of advanced EGFRm NSCLC and highlight key consideration factors.

Personalizing upfront treatment options for advanced EGFRm NSCLC

Novel GLP-1/FGF21 dual agonist shows promise in treatment of MASLD with T2DM

The glucagon-like peptide-1 (GLP-1) and fibroblast growth factor 21 (FGF21) dual agonist HEC88473 demonstrates an acceptable safety profile and potential efficacy in the management of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM).

Novel GLP-1/FGF21 dual agonist shows promise in treatment of MASLD with T2DM

Baricitinib compares favourably with filgotinib for RA

25 May 2025

In the treatment of patients with rheumatoid arthritis, baricitinib is equally effective as filgotinib at reducing disease activity, with similar drug retention rates, according to a retrospective study.

Baricitinib compares favourably with filgotinib for RA

25 May 2025

Full-spectrum microbiome drug for IBS with constipation clears phase II trial

25 May 2025 by

The next-generation oral full-spectrum microbiome drug EBX-102-02 appears to have an acceptable safety profile in patients with irritable bowel syndrome with constipation (IBS-C) while yielding improvements in symptom severity, abdominal pain, and stool consistency, according to the results of the phase IIa TrIuMPH* study.

Full-spectrum microbiome drug for IBS with constipation clears phase II trial

25 May 2025

Linerixibat quells cholestatic itch in PBC, enabling better sleep

The ileal bile acid transporter inhibitor linerixibat provides rapid and substantial relief from cholestatic pruritus, in turn reducing associated sleep disturbances, in patients with primary biliary cholangitis (PBC), as shown in the global, phase III GLISTEN trial.

Linerixibat quells cholestatic itch in PBC, enabling better sleep

23 May 2025

Adverse events push RA-ILD patients to discontinue nintedanib

In patients with rheumatoid arthritis (RA)-related interstitial lung disease (ILD), combination therapy with disease-modifying antirheumatic drugs (DMARDs) does not negatively influence the safety and efficacy of nintedanib, reports a study. The main drivers of drug withdrawal or dose reduction in these individuals are adverse events (AEs), primarily due to comorbidities.

Adverse events push RA-ILD patients to discontinue nintedanib

Tirzepatide boasts lower risk of GI side effects vs other GLP1-RAs

The use of tirzepatide delivers a better safety profile when compared to other glucagon-like peptide-1 receptor agonists (GLP-1RAs), as shown by the lower risk of gastrointestinal (GI) side effects associated with its use, reports a real-world study presented at DDW 2025.

Tirzepatide boasts lower risk of GI side effects vs other GLP1-RAs

GLP-1RAs help reduce risk of gastrointestinal cancers

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs), as opposed to insulin or metformin, provides a protective benefit against the development of gastrointestinal cancers, as shown in a study presented at DDW 2025.

GLP-1RAs help reduce risk of gastrointestinal cancers

Dupilumab improves disease severity, PROs in children with AD

Treatment with dupilumab improved disease severity and patient-reported outcomes (PROs) in paediatric patients aged <12 years with moderate-to-severe atopic dermatitis (AD), according to a 4-year interim analysis of the PEDISTAD* trial presented at PAS 2025.

Dupilumab improves disease severity, PROs in children with AD